Synaptogenix rises as Maxim initiates with 'buy'

TAO Synergies

12/04/2022 14:20

** Shares of drug developer  SNPX.O  up 1.7% at $7.15
premarket after Maxim Group initiates coverage with 'buy' rating
and $14 PT on potential of co's lead drug Bryostatin
    ** Bryostatin activates natural pathways in brain with
potential to treat many disorders, including Alzheimer's,
Parkinson's, Multiple Sclerosis and Fragile X Mental Retardation
syndrome
    ** Brokerage says while Alzheimer's drug development space
has largely focused on targeting the proteins - Aβ and Tau - 
Bryostatin brings differentiated approach to treating disease
    ** Models commercialization in U.S. and EU for Alzheimer's
disease in 2026 and 2027
    ** Stock down ~19% YTD

    
    

 (Reporting by Mrinalika Roy in Bengaluru)
 ((mrinalika.roy@thomsonreuters.com; within U.S. +1 646 223
8780, outside U.S. +91 806749 8325;))